11 Feb 2013 15:38
11 February 2013
e-Therapeutics plc ("e-Therapeutics" or the "Company")
Director/PDMR Shareholding
The Company received notification on 11 February 2013 that Novotech Investment Limited (NIL), a company of which Professor Malcolm Young (CEO) is a director and in which he has options to subscribe for ordinary shares, had sold 20,000 ordinary shares in e-Therapeutics plc at GBP0.30 per share on 8 February 2013. Professor Young had no knowledge of the proposed sale and, as one of three directors in NIL, had no ability by himself to prevent NIL from selling the shares. It is understood that NIL has disposed of the shares to enable NIL to discharge its obligations to third parties.
Following the sale, Professor Young's direct beneficial interest in the Company remains unchanged at 20,640,482 shares, representing 14.94% of the total issued share capital of the Company (of which 10,330,241 shares are held by Professor Young and 10,310,241 shares are held by Professor Young's wife). However, Professor Young's indirect holding relating to interests that he holds in NIL and Novotech Syndicate LLP has been reduced by 5,968 shares, and now stands at 397,180 shares, representing 0.29% of the total issued share capital of the Company.
-Ends-
For more information, please contact:
e-Therapeutics plc
Daniel Elger
Tel: +44 (0) 79 0991 5068
www.etherapeutics.co.uk
Panmure Gordon (UK) Limited
Investment Banking: Fred Walsh / Grishma Patel
Corporate Broking: Hannah Woodley
Tel: +44 (0) 20 7886 2500
www.panmure.com